{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457120720
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = 3funct
| source = axo
| target = [[HER2/neu]], [[CD3 receptor|CD3]]
<!-- Clinical data -->
| tradename = Rexomun
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 509077-99-0
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Ertumaxomab''' (trade name '''Rexomun''') is a [[rat]]-[[mouse|murine]] hybrid [[monoclonal antibody]] designed to treat some types of [[cancer]].  

It is a [[trifunctional antibody]] which works by linking [[T-lymphocyte]]s and [[macrophage]]s to the [[cancer cell]]s.<ref>[http://www.fresenius.se/internet/fag/com/faginpub.nsf/Content/P-Info2004_01_15 Fresenius ]</ref>

Phase II [[clinical trial]] evaluating the treatment of [[breast cancer]] was terminated due to change in [[Fresenius (company)|Fresenius]]' development plans.<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00522457 ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy]</ref> (So they could concentrate on their other product [[catumaxomab]] (trade name Removab).<ref>[https://www.fresenius.com/media/gb_englisch_IFRS_2009.pdf 2009 Consolidated Financial Statements and Management Report of Fresenius SE ]</ref>{{rp|35}})

==References==
{{Reflist|2}}


{{Monoclonals for tumors}}
{{Growth factor receptor modulators}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Immunology]]
[[Category:Abandoned drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}